finbox
0
All posts from finbox
finbox in Finbox,

A Review Of The Components Of The iShares Biotech ETF: Amgen

"AMGN remains one of the leading pioneers in the industry as they have brought numerous products to the marketplace. The success they have enjoyed allowed them to grow from an upstart to the biotech behemoth with sales of over $20 billion per year. The greatest challenge facing AMGN is the rise of biosimilar challenges that are now entering the marketplace. Unlike oral dosage forms, the biological products developed by AMGN have been relatively shielded from margin destroying biosimilars thus allowing AMGN to generate billions in sales from well-established products such as Epogen and Aranesp. Let's examine AMGN pipeline to discuss the growth path for AMGN share price as the years progress."

Full analysis by Alexander J. Poulos